Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis

New England Journal of Medicine

Volumn 365, Issue 16, 2011, Pages 1471-1481

  Blanc, François Xavier ^a   Sok, Thim ^c   Laureillard, Didier ^c,k   Borand, Laurence ^d   Rekacewicz, Claire ^l   Nerrienet, Eric ^d   Madec, Yoann ^m   Marcy, Olivier ^c   Chan, Sarin ^c   Prak, Narom ^e   Kim, Chindamony ^f,h   Lak, Khemarin Kim ^c,i   Hak, Chanroeurn ^g   Dim, Bunnet ^c,f,j   Sin, Chhun Im ^e   Sun, Sath ^c,i   Guillard, Bertrand ^d   Sar, Borann ^d   Vong, Sirenda ^d   Fernandez, Marcelo ^c   Fox, Lawrence ⁿ   Delfraissy, Jean François ^a,b,l   Goldfeld, Anne E ^c,o   more..

^a BICÊTRE HOSPITAL   (France)

^b INSERM   (France)

^c Cambodian Health Committee   (Cambodia)

^d INSTITUT PASTEUR DU CAMBODGE   (Cambodia)

^e Department of Infectious Diseases ^*  (Cambodia)

^f MÉDECINS SANS FRONTIÈRES   (Switzerland)

^g Calmette Hospital   (Cambodia)

^h Donkeo Provincial Hospital   (Cambodia)

ⁱ Svay Rieng Provincial Hospital   (Cambodia)

^j Siem Reap Provincial Hospital   (Cambodia)

^k HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^l International Research and Collaboration unit   (France)

^m INSTITUT PASTEUR   (France)

ⁿ NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^o BOSTON CHILDREN S HOSPITAL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; COTRIMOXAZOLE; EFAVIRENZ; ETHAMBUTOL; ISONIAZID; LAMIVUDINE; NEVIRAPINE; PYRAZINAMIDE; RIFAMPICIN; STAVUDINE; TUBERCULOSTATIC AGENT; VIRUS RNA;

ADULT; AGED; ANEMIA; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG SENSITIVITY; EARLY TREATMENT; ELECTROLYTE DISTURBANCE; EYE TOXICITY; FEMALE; GASTROINTESTINAL DISEASE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOTHYROIDISM; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; LATE TREATMENT; LIVER TOXICITY; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; METABOLIC DISORDER; MITOCHONDRIAL TOXICITY; MORTALITY; MULTICENTER STUDY; NEUROLOGIC DISEASE; NEUTROPENIA; OTOTOXICITY; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN TOXICITY; SURVIVAL; TREATMENT FAILURE; TUBERCULOSIS; VIRUS LOAD;

EID: 80054742528     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1013911     Document Type: Article

References (33)

1. Global tuberculosis control: WHO report 2010. Geneva: World Health Organization, 2010.
2. Mukadi YD, Maher D, Harries A. Tuberculosis case fatality rates in high HIV prevalence populations in sub-Saharan Africa. AIDS 2001;15:143-52. (Pubitemid 32142288)
3. Koenig SP, Riviere C, Leger P, et al. High mortality among patients with AIDS who received a diagnosis of tuberculosis in the first 3 months of antiretroviral therapy. Clin Infect Dis 2009;48:829-31.
4. Kyeyune R, den Boon S, Cattamanchi A, et al. Causes of early mortality in HIV-infected TB suspects in an East African referral hospital. J Acquir Immune Defic Syndr 2010;55:446-50.
5. Lawn SD, Churchyard G. Epidemiology of HIV-associated tuberculosis. Curr Opin HIV AIDS 2009;4:325-33.
6. Wood R. HIV/TB: when is it safe to start HAART? South Afr J HIV 2008;9(4):18-24.
7. Dannenberg AM Jr. Perspectives on clinical and preclinical testing of new tuberculosis vaccines. Clin Microbiol Rev 2010;23:781-94.
8. Abdool Karim SS, Naidoo K, Grobler A, et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med 2010;362:697-706.
9. Velasco M, Castilla V, Sanz J, et al. Effect of simultaneous use of highly active antiretroviral therapy on survival of HIV patients with tuberculosis. J Acquir Immune Defic Syndr 2009;50:148-52.
10. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach - 2010 revision. Geneva: World Health Organization, 2010.
11. Treatment of tuberculosis: guidelines. 4th ed. Geneva: World Health Organization, 2010.
12. Rouet F, Ekouevi DK, Chaix ML, et al. Transfer and evaluation of an automated, low-cost real-time reverse transcription-PCR test for diagnosis and monitoring of human immunodeficiency virus type 1 infection in a West African resource-limited setting. J Clin Microbiol 2005;43:2709-17. (Pubitemid 40827943)
13. Rouet F, Chaix ML, Nerrienet E, et al. Impact of HIV-1 genetic diversity on plasma HIV-1 RNA quantification: usefulness of the Agence Nationale de Recherches sur le SIDA second-generation long terminal repeat-based real-time reverse transcriptase polymerase chain reaction test. J Acquir Immune Defic Syndr 2007;45:380-8. (Pubitemid 47057665)
14. Tamura M, Khun KE, Yuos BH, et al. High prevalence/incidence of TB and poor outcomes of TB treatment among people living with HIV/AIDS (PLWHA) in Phnom Penh, Cambodia. Presented at the XV International AIDS Conference, Bangkok, Thailand, July 11-16, 2004. abstract. (http://www.iasociety.org/Default.aspx? pageId=11&abstractId=2173528.)
15. Thai S, Lynen L, Kimura K, et al. Public private partnership in tuberculosis control in Phnom Penh, Cambodia. Presented at the XV International AIDS Conference, Bangkok, Thailand, July 11-16, 2004. abstract. (http://www.iasociety.org/Default.aspx?pageId=11&abstractId=2170940.)
16. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. Br J Cancer 1976;34:585-612. (Pubitemid 8004970)
17. Slutsky AS, Lavery JV. Data safety and monitoring boards. N Engl J Med 2004;350:1143-7. (Pubitemid 38298996)
18. Assessing time-to-event as an endpoint: reporting survival analyses. In: Lang TA, Secic M. How to report statistics in medicine. 2nd ed. Philadelphia: American College of Physicians, 2006:115-24.
19. Cain KP, Anekthananon T, Burapat C, et al. Causes of death in HIV-infected persons who have tuberculosis, Thailand. Emerg Infect Dis 2009;15:258-64.
20. Lawn SD, Myer L, Bekker LG, Wood R. Burden of tuberculosis in an antiretroviral treatment programme in sub-Saharan Africa: impact on treatment outcomes and implications for tuberculosis control. AIDS 2006;20:1605-12. (Pubitemid 44162402)
21. Moore D, Liechty C, Ekwaru P, et al. Prevalence, incidence and mortality associated with tuberculosis in HIV-infected patients initiating antiretroviral therapy in rural Uganda. AIDS 2007;21:713-9. (Pubitemid 46568628)
22. Havlir DV, Kendall MA, Ive P, et al. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med 2011;365:1482-91.
23. Abdool Karim SS, Naidoo K, Grobler A, et al. Integration of antiretroviral therapy with tuberculosis treatment. N Engl J Med 2011;365:1492-501.
24. Varma JK, Nateniyom S, Akksilp S, et al. HIV care and treatment factors associated with improved survival during TB treatment in Thailand: an observational study. BMC Infect Dis 2009;9:42.
25. Harries AD, Chimzizi R, Zachariah R. Safety, effectiveness, and outcomes of concomitant use of highly active antiretroviral therapy with drugs for tuberculosis in resource-poor settings. Lancet 2006;367:944-5.
26. Müller M, Wandel S, Colebunders R, Attia S, Furrer H, Egger M. Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. Lancet Infect Dis 2010;10:251-61.
27. Lawn SD, Bekker LG, Miller RF. Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals. Lancet Infect Dis 2005;5:361-73. (Pubitemid 40779257)
28. Meintjes G, Wilkinson RJ, Morroni C, et al. Randomized placebo-controlled trial of prednisone for paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome. AIDS 2010;24:2381-90.
29. Spire B, Carrieri P, Sopha P, et al. Adherence to antiretroviral therapy in patients enrolled in a comprehensive care program in Cambodia: a 24-month follow-up assessment. Antivir Ther 2008;13:697-703.
30. Goldfeld AE, Corbett EL. TB/AIDS coinfection: an integrated clinical and research response. In: Kaufman S, Walker BD, eds. AIDS and tuberculosis: a deadly liaison. Infection biology series. Weinheim, Germany: Wiley-VCH Verlag, 2009:209-52.
31. Thim S, Sath S, Sina M, et al. A community-based tuberculosis program in Cambodia. JAMA 2004;292:566-8.
32. Ferradini L, Laureillard D, Prak N, et al. Positive outcomes of HAART at 24 months in HIV-infected patients in Cambodia. AIDS 2007;21:2293-301. (Pubitemid 350287455)
33. Lawn SD, Little F, Bekker LG, et al. Changing mortality risk associated with CD4 cell response to antiretroviral therapy in South Africa. AIDS 2009;23:335-42.